Last edition
News about "two denosumab biosimilars"
Teva secures EC approval for two denosumab biosimilars, Ponlimsi and Degevma
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., has received marketing authorizations from the European Commission for its two denosumab biosimilars—Ponlimsi, referencing Prolia, and Degevma, referencing Xgeva.
Two Denosumab Biosimilars | 27/11/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members